By Susan Heavey
WASHINGTON (Reuters) - A month after a new U.S. law encouraging the development of medicines to counter bioterrorism, some drugmakers are lobbying for more incentives to make products that may never be used.
Additional financial lures could include liability protection, tax breaks and a potentially controversial provision that would extend patents on blockbuster drugs not related to U.S. efforts to fight terrorism.
<snip>
One lure that could attract larger companies is a patent provision that would give firms longer exclusivity on a popular drug in exchange for developing one to combat bioterror.
<snip>
"Why should people who buy those (non-terror) drugs ... be taxed to fund bioterrism research," Goozner said. "Isn't that something that should be funded by the United States government?"
more...
http://story.news.yahoo.com/news?tmpl=story2&u=/nm/20040822/hl_nm/health_bioshield_dc